Navigation Links
Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
Date:3/2/2011

NEW YORK and OSAKA, Japan, March 2, 2011 /PRNewswire/ -- Intra-Cellular Therapies, Inc. ("ITI") and Takeda Pharmaceutical Company Limited (TSE: 4502, "Takeda"), today announced that they have entered into an exclusive collaboration to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors, discovered by ITI, for the treatment of cognitive impairment associated with schizophrenia. This agreement is targeted worldwide, but ITI has retained the option to co-promote with Takeda in the United States.

ITI's PDE1 inhibitors are unique, orally available, preclinical stage compounds. These compounds have potential to be treatments for a variety of psychiatric and neurological diseases.

Under the terms of the agreement, ITI will receive an upfront cash payment and will be eligible to receive payments of approximately $500 million in the aggregate upon achievement of certain development milestones and up to an additional $250 million in the aggregate upon achievement of certain sales-based milestones, along with tiered royalty payments based on net sales by Takeda. Takeda will be solely responsible for development, manufacturing and commercialization of PDE1 inhibitors.

"Takeda's strength in CNS drug development and commercialization complements ITI's innovative approach to discovery, research and development," said Sharon Mates, Chairman and CEO of Intra-Cellular Therapies, Inc. "We are delighted to be working together with Takeda to advance the development of our novel PDE1 inhibitors. This program represents a unique approach to the treatment of cognitive impairment associated with schizophrenia (CIAS) and other disorders."

"We are able to enhance our central nervous system pipeline, one of our Core Therapeutic Areas, through this collaboration," said Shigenori Ohkawa, a member of the Board and Executive Vice President, Chief Scientific Officer of Takeda Pharmaceutical Company Limited. "We believe that ITI's PDE1 inhib
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia
2. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
3. Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
4. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
5. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
6. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
7. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
8. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
9. Reportlinker Adds Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets
10. Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies
11. The Blanchette Rockefeller Neurosciences Institute Identifies Groundbreaking New Therapies for Prevention and Treatment of Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... VIEJO, Calif. , Dec. 22, 2014 ... into expanded corporate offices in Aliso Viejo ... announced that due to the tremendous growth and worldwide ... needed. Sales of patented SnoreRx, the anti snore cure ... offices. He said, "We are now in 23 ...
(Date:12/22/2014)... a privately-held medical products and technologies company, today announced ... Officer of the company, effective December 22, 2014. ... Board of Directors of ConvaTec thanks Mr. Berger for ... years," said Magnus Lundberg , the Chairman of ... company is well positioned for the future."  The company ...
(Date:12/22/2014)... 2014  Mark Farrah Associates (MFA), www.markfarrah.com ... of the 2015 marketplace exchange projections and insights ... According to a recent ASPE (Office of ... of Health and Human Services) report, an estimated ... plans through the Marketplace as of October 2014 ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Insights into the Marketplace and Individual Market Growth 2
... importance of dedicated information management systems for radiation ... most recent version of its MOSAIQ® Oncology Information ... Systems Society,s 2012 conference (HIMSS12), Feb. 20-24, in ... comprehensive OIS that centralizes traditional radiation oncology, particle ...
... Feb. 16, 2012  Cardium Therapeutics (NYSE Amex: ... previously announced sale of 17,857,143 shares of its common ... of approximately $5.0 million, before deducting placement agent,s fees ... investors participating in the offering purchased the shares at ...
Cached Medicine Technology:Elekta Highlights Latest Version of MOSAIQ Oncology Information System at HIMSS12 Meeting 2Cardium Announces Closing of $5.0 Million Equity Financing 2Cardium Announces Closing of $5.0 Million Equity Financing 3
(Date:12/22/2014)... Physicians in China are most eagerly awaiting a ... lymphoma (NHL), according to a new report from ... MabThera is the only biologic available to treat diffuse ... NHL. , According to Kantar Health’s report, “Biosimilars in ... in China has been growing and is expected to ...
(Date:12/22/2014)... Super Saturday, the last Saturday before ... the busiest day in the 2014 holiday shopping season. ... had a steady pre-Christmas stream of customers, ready to ... , “I definitely intend to take advantage…of the recreational ... who was enjoying The Grass Station’s holiday sale on ...
(Date:12/22/2014)... 22, 2014 Only weeks following the ... mid-western cities to have a battery manufacturer create 29 ... ( http://www.talklocal.com ) is launching in Henderson to ... , “A strong manufacturing sector is going to build ... Singh explained, “and TalkLocal works with small businesses that ...
(Date:12/22/2014)... In recognition of Veteran’s Day, Discount Labels ... a local organization that provides services to veterans and ... on a couple hundred acres in the hills of ... class fishing, hunting, hiking, horseback riding, 4-wheeling, skeet shooting, ... ago to support U.S. Service men and women, police ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Pasadena ... offering consultations for sleep apnea. Drowsy drivers are 15 ... drivers who are well-rested, and some experts believe that ... roads as intoxicated drivers. Unfortunately, millions of Americans may ... American Academy of Sleep Medicine, about 18 million Americans ...
Breaking Medicine News(10 mins):Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2Health News:TalkLocal Launches in Henderson Weeks Following New Megafactory, New Jobs Announcement 2Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2
... adolescents and young adults finds that an extensive set ... of asthma attacks in participants who both receive care ... This finding differs from previous reports suggesting that ... future asthma attacks. These earlier conclusions, however, were based ...
... of blocking the formation of specific protein clumps that ... been discovered by researchers at the University of Pennsylvania ... they have identified drug-like inhibitors of AD tau protein ... Co-authors Alex Crowe, Research Specialist; Kurt R. ...
... , , Campaign couples power ... , HARRISBURG, Pa., Aug. 10 /PRNewswire-USNewswire/ -- ... Health Action Now campaign with a multimillion-dollar national advertising and grassroots ... dependable, affordable health insurance. The Association,s paid advertising -- available ...
... , PITTSBURGH, Aug. 10 DynaVox Mayer-Johnson, ... for individuals with speech, language and learning disabilities, today ... standard for hand-held speech solutions by bringing together comprehensive ... of mainstream communication features. , , ...
... other contact sports, study finds , MONDAY, Aug. 10 (HealthDay ... about the same rate as in baseball and football, deaths ... common in lacrosse, new research shows. , Lacrosse has swept ... making it the fastest-growing youth sport in the country. The ...
... , , HUDSON, Mass., Aug. 10 ... provider of high performance interconnect solutions for the most ... series circular connectors were selected by SynCardia Systems, Inc. ... to provide critical interconnect reliability for their Freedom(TM) driver, ...
Cached Medicine News:Health News:NIAID media availability: Still searching for predictors of asthma attacks 2Health News:New class of compounds discovered for potential Alzheimer's disease drug 2Health News:New class of compounds discovered for potential Alzheimer's disease drug 3Health News:Multimillion-Dollar AARP Campaign Busts the Myths of the Health Care Debate 2Health News:Multimillion-Dollar AARP Campaign Busts the Myths of the Health Care Debate 3Health News:DynaVox Mayer-Johnson Announces the Xpress 2Health News:DynaVox Mayer-Johnson Announces the Xpress 3Health News:Blows to the Chest Up Death Risk for Lacrosse Players 2Health News:Blows to the Chest Up Death Risk for Lacrosse Players 3Health News:Hypertronics HyperGrip(R) and D Series Connectors Selected for SynCardia's Total Artificial Heart 2
Research Series 2100 Adjustable-volume Pipette,100-1,000 l, single-channel with adjustable-volume setting...
... first Sysmex hematology analyzer designed for a ... its small footprint, closed tube sampling, and ... of whole blood sample, you have a ... the emergency room, surgical suite, or small ...
... The Integrity family of pacemakers ... and truly automatic devices in today's ... combination of automated features and diagnostic ... popular and proven Affinity pacemakers platform. ...
... PT System is an in vitro diagnostic ... results, expressed in seconds and INR units. ... It is intended for use by health ... to monitor patients who are on warfarin-type ...
Medicine Products: